STOCK TITAN

Fennec Pharmaceuticals (FENC) 10-K Filings

FENC NASDAQ

Here are the 10-K annual reports from Fennec Pharmaceuticals Inc. (FENC) in our archive since June 2025, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.

A 10-K covers the audited annual report, with the full financial statements, so if you follow FENC and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full FENC filings page.

Rhea-AI Summary

Fennec Pharmaceuticals is a commercial-stage specialty pharma company focused on preventing cisplatin-induced hearing loss with its drug PEDMARK in the U.S. and PEDMARQSI in Europe and other regions. The product is FDA- and European Commission-approved for pediatric patients with localized, non-metastatic solid tumors and showed about a 50% relative reduction in hearing loss versus cisplatin alone in clinical studies.

In March 2024, Fennec signed an exclusive licensing deal with Norgine, receiving about $43 million upfront, with up to about $230 million in potential milestones and double-digit tiered royalties on PEDMARQSI net sales. Norgine launched PEDMARQSI in Germany and the U.K. in 2025, with further European launches expected. Fennec also added a 2025 distribution agreement with Inpharmus for Turkey and Gulf Cooperation Council countries and reported positive 2025 Japanese STS-J01 trial results, supporting a registration strategy and potential partnering there.

The company has U.S. Orphan Drug Exclusivity for PEDMARK until September 20, 2029 and European pediatric-use marketing exclusivity until May 26, 2033, alongside a broad patent estate expiring around 2039. In March 2026, Fennec settled litigation with Cipla over a proposed generic, with Cipla agreeing not to launch its sodium thiosulfate product before September 1, 2033, reinforcing PEDMARK’s commercial runway.